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Background: The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression
in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well
as the prognostic impact on overall survival (OS).
Methods: We analyzed a total of 294 patients (m, n = 184; f, n = 110) with SCLC (stage IIIA, n = 32; IIIB, n = 87; IV, n = 175)
diagnosed in our institution between January 2005 and December 2008. Patient’s characteristics comprising age, gender,
histology and first line treatment were included into the analyses. For the follow-up of patients the governmental death
registrar was used. The TTF-1 immunostaining was prospectively performed. CT scans of all patients were reviewed and
response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) criteria.
Results: A total of 221 of the 294 patients were eligible for analysis. Patients with TTF-1-positive SCLC had a median OS
of 374 (95% CI 306–442) days. The OS of patients with TTF1-negative SCLC was 290 (95% CI 191–389) days, which was
not significantly shorter (p = 0.254). Also stratification for tumor stage did not reveal significant difference in OS. Analyzing
the disease control rate (DCR) in patients with metastatic disease (stage IV), we observed a significantly (p = 0.006)
improved response to treatment in the group of patients with TTF-1-expression (DCR 86% vs. 56%). Regarding the
overall response rates (ORR) in the entire population, there was no difference observed between both subgroups.
(TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%; p = 0.642).
Conclusions: The diagnostic information of TTF-1 in SCLC seems to be limited. TTF-1 had no prognostic value concerning
OS, but may serve as a predictor for response to first line chemotherapy.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
5811254651472285
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The DNA-binding protein thyroid transcription factor 1
(TTF-1) is mainly expressed in the thyroid gland and the
lungs and plays an important role in the development of
these organs. It is expressed in type II pneumocytes and
Clara cells and has a crucial part in regulating the ex-
pression of various genes, such as for the surfactant or
the Clara cell protein [1-5].* Correspondence: torsten.bauer@helios-kliniken.de
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unless otherwise stated.It is known that the expression of TTF-1 is helpful to
distinguish primary lung cancer from other non-
pulmonary malignancies. The expression differs among
the different histologic subtypes of lung carcinoma [6-9].
While TTF-1-expression was found to be frequent in
adenocarcinoma and small cell lung cancer, it appears to
be rare in patients with squamous or large cell carcin-
oma. In SCLC, the expression of TTF-1 was found in
about 85-90% of cases [10]. Furthermore, it has been de-
scribed that non-pulmonary small cell carcinoma can ex-
press TTF-1 due to their neuroendocrine differentiation
[11]. Thus, the diagnostic value of TTF-1 in SCLCThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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esis of lung or thyroid cancer remains unclear, although
there is evidence that it may be associated with the neu-
roendocrine differentiation of tumor cells [12].
Recent studies were addressed to the prognostic value
of TTF-1-expression in lung carcinoma. Concerning
NSCLC, TTF-1-expression is associated with better
overall survival, which is even more pronounced in the
subgroup of patients with adenocarcinoma [9,13-16]. A
further aspect of any biomarker is its possible predictive
value concerning response to chemotherapy. To our
knowledge, there is currently no study which analyzed
overall survival as well as response to first line chemo-
therapy of SCLC according to TTF-1-expression.
Therefore, the present study analyzes the frequency of
TTF-1-expression in patients with locally advanced or
metastatic small cell lung cancer and its prognostic value
concerning overall survival as well as the predictive
value for response to treatment.
Methods
Patient’s data and data acquisition
We retrospectively analyzed 294 patients (male, n = 184;
female, n = 110) who were treated for histologically proven
locally advanced or metastatic small cell lung cancer in
our institution between January 2005 and December 2008.
Patients characteristics were entered into a database and
the following parameters were extracted for analysis: Age,
gender, date of diagnosis, TNM classification (UICC 6) [17],
initial therapy including chemotherapy and radiotherapy,Figure 1 Example of TTF-1 negative small cell lung cancer (SCLC) stai
panel: Neural cell adhesion molecule (CD56). Left lower panel: Ki-67 Proliferationresponse to first line treatment according to RECIST 1.0
[18] and the TTF-1 status of the diagnostic specimen. The
TTF-1-immunostaining was performed prospectively using
standard immunohistochemistry (Antibody Clone TTF-1
SP141, Ventana Medical Systems, DAB detection Kit). The
immunostained cells were considered positive only when
distinct nuclear staining was identified [19]. The tumor
was identified as TTF-1 positive when more than 5% of
cells stained for TTF-1. Further immunohistochemical
markers stained were CD56, KL-1 or CKMNF-116 and
MIB-1 [Figures 1 and 2].
Survival of these patients was followed up on a regular
basis and mortality data were verified every six month
with the governmental death registrar.
Data were gathered for internal quality control on a rou-
tine basis and all patients gave informed consent for data
collection. The institutional review board (IRB-LungClinic
Heckeshorn) therefore waived the need for ethical com-
mittee approval.
Therapy
Standard therapy in our institution comprised chemother-
apy, radiation and their combination. Standard chemother-
apy in all stages comprised cisplatin (80 – 100 mg/m2 body
surface, d1) or carboplatin (AUC 5 in cases with renal insuf-
ficiency with a glomerolar filtration rate < 60 ml/h) in com-
bination with etoposide (100 – 140 mg/m2 body surface,
d1-3). A combination radiochemotherapy was considered
in stage III and applied simultaneously or sequentially ac-
cording to the performance status of the patients.ning. Left upper panel: Hematoxylin and eosin stain (HE). Right upper
marker (Clone MIB-1). Right lower panel: Thyroid transcription factor-1 (TTF-1).
Figure 2 Example of TTF-1 positive small cell lung cancer (SCLC) staining. The tumor was identified as TTF-1 positive when more than 5%
of cells stained for TTF-1. Left upper panel: Hematoxylin and eosin stain (HE). Right upper panel: Neural cell adhesion molecule (CD56). Left lower
panel: Ki-67 Proliferation marker (Clone MIB-1). Right lower panel: Thyroid transcription factor-1 (TTF-1).
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control of tumor deposits, i.e. of bone or brain metastases.
Patients diagnosed in stage IV received preferably stand-
ard palliative chemotherapy as described above. All other
lines of chemotherapy were noted until the patient died or
cases were censored for this analysis. The number of lines
is reported per patient. According to the treating physician
best supportive care was applied in patient with low func-
tional status and/or denied informed consent for therapy.Response to therapy
Patients on treatment were followed-up on a regular basis,
performing a chest CT and a CT of the upper abdomen
(including the adrenal glands) every second cycle. The
final staging for the response evaluation to first line
chemotherapy was performed 3 weeks +/− 7 days after
completion of first line treatment. The response was de-
fined according to RECIST 1.0 [18]: Complete Response
(CR) meaning complete disappearance of all target lesions;
Partial Response (PR) meaning at least 30% reduction of
the sum of all target lesions longest diameters; Progressive
Disease (PD) meaning at least 20% increase of the sum of
all target lesions longest diameters, taking as reference the
smallest measurements recorded since the treatment
started and Stable Disease (SD) being defined as neither
sufficient shrinkage to qualify for PR nor sufficient de-
crease to qualify for PD.
The disease control rate (DCR) was defined as all pa-
tients showing at least a stable disease after first linetreatment whereas the overall response rate comprised
only patients with a complete or partial response.
Statistical analysis
All frequencies are reported as number and percentage.
Continuous variables are reported as mean ± standard de-
viation. Frequencies were analyzed with Chi-square statis-
tics with Fisher’s exact test were needed. The disease
control rate (DCR) was analyzed according to the effects
of stage (III vs. IV) and TTF-1-status with a Chi-square
test with layer analysis (Mantel-Haenszel statistics). Con-
tinuous survival was analyzed with Kaplan-Meier statistics
and strata were compared with log-rank analyses. Survival
time is reported as median days and the 95% confidence
interval. All analyses were carried out with the Statistical
package for Social Sciences (SPSS® Version 19.0) on a
Microsoft Windows® operating system.
Results
Mean age of all patients was 64.1 ± 10.2 years (n = 294). A
total of 119/294 patients (40.5%) had stage III (IIIA, n = 32,
10.9%; IIIB, n = 87, 29.6%) and 175/294 patients (59.5%)
had stage IV SCLC according to the UICC-6 staging
system.
Of the patients with stage III disease (n = 119/294, 40.5%),
70/119 (58.8%) received combined radio- and chemotherapy
(simultaneous n = 50, 42.0%; sequential, n = 20, 16.8%; all
platinum-based) as first line therapy, whereas 6/119 patients
(5.0%) had chemotherapy with palliative radiotherapy (i.e.
incomplete dose) only. 30/119 patients (25.2%) received
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(definitive n = 3, 2.5%; palliative n = 5, 4.2%). Best support-
ive care was applied in 4/119 cases (3.4%) and 1/119 ther-
apies could not be retrieved. A total of 30/119 patients
(25.2%) had prophylactic brain irradiation followed by of
systemic treatment.
In the population of the patients with stage IV (n = 175/
294, 59.5%) small cell lung cancer, 160/175 (91.4%) received
palliative chemotherapy (platinum-based, n = 154/160,
96%) for systemic treatment. Out of these, 52/160 patients
(32.5%) additionally received palliative radiotherapy due to
brain metastases (n = 24), bone metastases (n = 12) or for
local control of thoracic tumor sites (n = 21). After pallia-
tive chemotherapy, 9/175 patients (5.1%) had prophylactic
brain irradiation. 7/175 patients (4.0%) received only pal-
liative radiotherapy. Best supportive care was administered
in 4/175 patients (2.3%). No information on therapeutic
regime was available for 2/175 cases (1.2%).
TTF-1 immunhistochemistry was available for 221/294
patients (75.2%) of the entire population. Of these, 38/221
(17.2%) had TTF-1 negative small cell lung cancer,
whereas 183/221 (82.8%) tumors showed reactivity in
TTF-1 immunostaining. The distribution of gender was
equal in both groups. Comparing the percentage of TTF-1
negative tumors according to stage, no significant differ-
ence was observed [Table 1].
Of the patients included into the per protocol analyses
181/221 (81.9%) died during the observation period. The
median overall survival of all patients with known TTF-
1-status was 341 days (95% CI 282–400 days). Patients
with stage IV disease showed a significant shorter overall
survival (290 [95% CI 249–331] days) as compared to
those with stage IIIA (488 [95% CI 352–624] days) and
IIIB disease (451 [95% CI 354–548] days; p < 0.001 log
rank analysis for all strata).
Stratifying for the TTF-1-status, median overall survival
of all patients with TTF-1 positive tumors was 374 (95%
CI 306–442) days. Patients with TTF-1 negative SCLC
had a median overall survival of 290 (95% CI 191–389)
days, which was not significantly different from those withTable 1 Patient characteristics
all TTF1
Entire population 221 183/
Age (mean ± SD) 64.7 ± 10.2 64.0
Female n (%) 76/221 (34.4) 63/1
Male n (%) 145/221 (66.6) 120/
Stage IIIA n (%) 21/221 (9.5) 16/1
Stage IIIB n (%) 64/221 (29.0) 56/1
Stage IV n (%) 136/221 (61.5) 111/
Overview of the proportion of patients with TTF1-positive and TTF1-negative SCLC
*Student’s T-Test.
**Chi-Square Test.TTF-1 positive disease (p = 0.254). When analyzing the
overall survival according to TTF-1 for the different stage
groups, no significant difference was observed for stage IV
(p = 0.237) as well as for IIIA (p = 0.852) and IIIB patients
(p = 0.506) [Table 2 and Figure 3].
For the analysis of response to treatment according to
TTF-1-status of the tumor, patients were excluded when
no therapy or best supportive care (n = 18) was applied
or response to treatment was not available (n = 25).
Therefore, 178/221 (77.1%) of all patients with known
TTF-1-expression were eligible. Of these, 28/178 pa-
tients (15.7%) had TTF-1 negative SCLC.
Analyzing univariately the disease control rate (DCR), we
observed a significantly (p = 0.013) improved response to
treatment in the group of patients with TTF-1-expression
(DCR 135/150 (90%), CR, n = 8; PR, n = 105; SD, n = 22;
PD, n = 15) as compared to those without TTF-1-
expression (DCR 20/28 (71.4%); CR, n = 4; PR, n = 16; SD,
n = 0; PD, n = 8). Regarding the overall response rates
(ORR) in the entire population of stage III and IV pa-
tients, the number of patients showing at least a partial
remission was only slightly different between both
groups (TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%) failing
to reach the level of significance (p = 0.642) [Table 3].
When the DCR was analyzed separately for non-
metastatic (stage III) and metastatic patients (stage IV),
it was significantly higher in patients with TTF-1-
positive SCLC in stage IV (79/92, 85.9%) compared to
patients in the similar stage but with TTF-1-negative car-
cinoma (10/18, 55.6%; p = 0.006). This analysis did not
show any difference in stage III patients because the DCR
was very high for both groups of patients (DCR TTF-1-
pos. 56/58 96% versus TTF-1-neg. 10/10 100%; p = 0.726).
Discussion
TTF-1 is an immunhistochemical marker, which can help
to differentiate between primary lung carcinoma and non-
pulmonary cancer. In NSCLC, TTF-1-expression occurs
mainly in adenocarcinoma and plays a crucial role in differ-
entiating primary lung adenocarcinoma from pulmonary+ TTF1 - p-value
221 (82.8%) 38/221 (17.2%)
± 10.2 68.1 ± 9.6 0.023*
83 (34.4%) 13/38 (34.2%) 1.000**
183 (65.6%) 25/38 (65.8%)
83 (8.7%) 5/38 (13.2%)
83 (30.6%) 8/38 (21.0%)
183 (60.7%) 25/38 (65.8%) 0.412**
in the entire patient population and in the different stage groups.
Table 2 Overall survival (OS) in days according to TTF1 in
the entire population and in the subgroups of patients
with stage IIIA, IIIB and IV disease
TTF1 + TTF1 - p-value*
Entire population 374 (306–441) 290 (191–389) 0.254
Stage IIIA 533 (361–704) 488 (172–803) 0.852
Stage IIIB 512 (413–610) 282 (87–477) 0.506
Stage IV 302 (253–351) 227 (58–396) 0.273
*log-rank analyses.
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was found to be very frequent in various studies. However,
a review of the literature reveals that SCLC show a lack of
TTF-1 expression in about 10–15% of all cases
([6,7,21-25]). This is in line with the results of our study,
where 17% of SCLC did not show TTF-1-expression. The
frequency was neither associated with disease stage (III or
IV), age nor gender.
Various studies investigated the immunhistochemical
expression pattern of non-pulmonary small cell carcin-
oma, such as prostate or gastrointestinal SCC, revealing
discrepant results. While Ordanez et al. found TTF-1-
expression in only 4 of 54 cases, another study by YaoFigure 3 Survival Analysis and sub-analysis for disease stage according to
ITT = intention to treat). Left upper panel: ITT (n = 294) vs. PP population (n =
TTF-1 negative patients (n = 38; p = 0.516). Left lower panel: PP sub-population
negative patients (n = 13; p = 0.990). Right lower panel: PP sub-population with m
(n= 25; p = 0.313).et al. on 18 patients with small cell prostate carcinoma
showed TTF-1-expression in 83% of cases [10,11]. This
indicates that TTF-1 is not an exclusively pulmonologi-
cal marker but rather points towards a neuroendocrine
origin of the neoplastic cell [1,12]. This is strengthened
by the fact that non-pulmonary SCC as well as SCLC ex-
press other neuroendocrine markers such as chromogra-
nin A, neuro-specific enolase (NSE), CD57 or CD56
[26-31]. Therefore, the value of TTF-1 for origin-
diagnosis of small cell carcinoma seems to be dispens-
able, especially as the therapeutic approaches in cases of
SCC do usually not differ according to the origin if the
primary tumor site.
Another aspect of TTF-1-expression is a potentially
possible predictive value on overall survival of lung can-
cer patients. For NSCLC, there seems to be evidence
that patients with TTF-1 positive tumors show improved
overall survival compared to those with TTF-1 negative
tumors [9,13-16,23]. In our survival analyses including
221 SCLC patients, no significant difference could be
shown for the comparison between patients with differ-
ent TTF-1-expression. After stratifying for stage of dis-
ease, the results persisted in the subgroups of patients
with stage III as well as stage IV disease.TTF-1 (Kaplan-Meier plots with log-rank analysis; PP = per protocol,
221; p = 0.331). Right upper panel: PP population: TTF-1 positive (n = 183) vs.
with non-metastatic disease (n = 85): TTF-1 positive (n = 72) vs. TTF-1
etastatic disease (n = 136): TTF-1 positive (n =111) vs. TTF-1 negative patients
Table 3 Response to treatment according to TTF1-expression
(n = 178)
TTF1 + 150 (84.3%) TTF1 –n = 28 (15.7%) p-value
CR 8 (5.3%) 4 (14.3%)
PR 105 (70.0%) 16 (57.1%)
SD 22 (14.7%) 0
PD 15 (10.0%) 8 (28.6%) 0.003
RR 75.3% 71.4% 0.642
DCR (overall) 135 (90.0%) 20 (71.4%) 0.013
DCR stage III 56/58 (96.6%) 10/10 (100%) 0.726
DCR stage IV 79/92 (85.9%) 10/18 (55.6%) 0.006
Overall response rate (RR) is defined as the proportion of patients having at
least a partial response according to RECIST1.0. Disease control rate (DCR) is
defined as all patients with at least a stable disease according to RECIST1.0.
(CR = complete response; PR = partial response; SD = stable disease;
PD = progressive disease).
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RECIST, the response rates of first line chemotherapy in
the population of SCLC patients are known to be high
in contrast to NSCLC. However, a number of approxi-
mately 10-20% of all SCLC does not respond to first line
chemotherapy. The reason for that is mainly unknown.
As the chemotherapy is known to cause significant side
effects decreasing the quality of life of patients, it is of
essential need to identify markers that may predict re-
sponse to chemotherapeutic treatment. To our knowledge,
there is currently no other study addressed to the possible
implication of TTF-1-expression on response to chemo-
therapy in SCLC. In our analysis, a significantly higher dis-
ease control rate (DCR) in the group of TTF-1-positive
SCLC could be shown, assuming a higher chemosensitivity
of these tumors. Stratified by stage, this effect was highly
significant in stage IV but could not be reproduced in stage
III. We see this as a result of the high radiation rate in the
stage III subgroup (overall 70.5%), masking the presumed
lower chemosensitivity of TTF-1-negative tumors.
Although this was a strong effect in metastatic disease,
this difference did not result in a relevant overall sur-
vival benefit. Furthermore, response rates are still high
in the subgroup of TTF-1-negative patients (>55%),
which does not allow a reliable identification of patients
not benefiting from platinum based chemotherapy with
TTF-1 only. If TTF-1 could be of predictive value used
side-by-side with other biomarkers (i.e. MIB-1) should
be investigated in further studies.
Conclusions
In summary, the diagnostic value of routine immunhis-
tochemistry of TTF-1 in case of suspected SCLC appears
to be low. Concerning the diagnostic aspect, the morph-
ology of tumor cells and other immunhistochemical
markers, such as chromogranin A, neuro-specific eno-
lase (NSE), CD57 or CD56, are sufficient to enable thediagnosis of small cell cancer with neuroendocrine dif-
ferentiation. As TTF-1 can be missing in case of SCLC
and as well be present in case of non-pulmonary SCC, it
seems to be of limited value for the definition of the pri-
mary tumor.
Concerning the prognostic aspect, our data indicate
no prognostic implication of TTF-1-expression in SCLC
patients. However, we observed a strong association be-
tween the absence of TTF-1-expression and the risk of
first line failure in patients receiving platinum based
chemotherapy only.
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